Fresenius (NYSE:FMS) said today that it’s extending the deadline to close the $2 billion buyout of NxStage Medical (NSDQ:NXTM) by 90 days and posted second-quarter earnings that beat the consensus forecast. The German dialysis giant said it moved the merger deadline from August 7 to Nov. 5, but still expects to close the deal this year. […]
UPDATE: NxStage deals bloodlines biz to B Braun to mollify FTC in sale to Fresenius
UPDATE: Now includes information from NxStage indicating that the sale was part of the process to obtain FTC clearance for its sale to Fresenius. B. Braun said today it inked a deal to acquire the NxStage Medical‘s (NSDQ:NXTM) bloodlines business, which operates under the Medisystems moniker. Bethlehem, Penn.-based B. Braun did not release any details of the […]
NxStage touts reduced technique failure in Nx2me home hemodialysis study
NxStage Medical (NSDQ:NXTM) today released the results from a study of its Nx2me connected health remote patient management system for patients using home hemodialysis, touting a 29% reduction in technique failure of conversion to in-center hemodialysis by 29%. Results from the study were published in the journal Hemodialysis International, the Lawrence, Mass.-based company said. Data came from […]
NxStage shares dip on Q3 EPS miss
Shares in NxStage Medical (NSDQ:NXTM) have fallen slightly today after the medical device maker missed expectations on Wall Street with its third quarter earnings results. The Lawrence, Mass.-based company posted losses of $8.9 million, or 14¢ per share, on sales of $97.3 million for the 3 months ended September 30, seeing losses grow nearly 900% while […]
FTC seeks more information on Fresenius’ $2B NxStage buy
Fresenius Medical Care (NYSE:FMS; ETR:FRE) and NxStage Medical (NSDQ:NXTM) have received a request from the US Federal Trade Commission asking for more information on Fresenius’ $2 billion acquisition of NxStage, according to an SEC filing. The companies originally announced the acquisition in August, with Fresenius looking to pay $30 per share for Lawrence, Mass.-based home hemodialysis developer […]
NxStage Medical wins expanded FDA nod for System One home hemodialysis system
NxStage Medical (NSDQ:NXTM) said today it won expanded FDA clearance for its System One home hemodialysis system, clearing it for use without a care partner during waking hours. The system won initial clearance in 2005 and added clearance for home nocturnal hemodialysis in 2014, the Lawrence, Mass.-based company said, but has always required a care […]
NxStage Medical’s Todd Snell talks FDA, Brexit & regulatory strategy
Between the consequences of Brexit and a new commissioner at the FDA, executives across medtech are bracing for change within the global regulatory landscape. NxStage Medical‘s (NSDQ:NXTM) SVP of quality assurance, regulatory & clinical affairs, Todd Snell, spoke with MassDevice.com editor Sarah Faulkner about what he’s observing from his post at the Lawrence, Mass.-based company. Faulkner: What […]
Fresenius to pay $2B for NxStage Medical
Fresenius Medical Care (NYSE:FMS; ETR:FRE) said today that it agreed to pay $2 billion to acquire NxStage Medical (NSDQ:NXTM) and the home hemodialysis technology it developed. The $30-per-share deal, which is expected to close this year, represents a 29.6% premium on the August 4 closing price of $23.14 for NXTM shares. The stock was up 25.5% […]
NxStage wins FDA nod for next-gen System One hemodialysis system
NxStage Medical (NSDQ:NXTM) said today it won FDA 510(k) clearance for its next generation System One hemodialysis system. The newly cleared system includes a new touchscreen user interface and integrated blood pressure monitor designed to enhance ease of use for home hemodialysis patients, the Lawrence, Mass.-based company said. “Early customer and patient feedback in the UK on our next […]
NxStage Medical meets Q1 earnings forecast, beats on sales
NxStage Medical (NSDQ:NXTM) today met the consensus forecast for its 1st-quarter earnings and topped the revenue expectation on Wall Street. The dialysis device maker narrowed its losses by -6.8% to -$1.2 million, or -2¢ per share, on sales of $96.8 million for the 3 months ended March 31, for top-line growth of 8.5% compared with […]
NxStage wins CE Mark for next-gen System One hemodialysis system
NxStage Medical (NSDQ:NXTM) said today it won CE Mark approval in the European Union for its next-gen System One hemodialysis system. The newly cleared system incldues a new touchscreen user interface and integrated blood pressure montior designed to enhance ease of use for home hemodialysis patients, the Lawrence, Mass.-based company said. “Our next generation system was […]
- 1
- 2
- 3
- …
- 12
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
Google+